Pyridinylpyrazole PLK1 Inhibitors With Selective Anticancer Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PLK1 inhibitors face challenges in clinical trials due to cytotoxicity and lack of efficacy, necessitating the development of a PLK1 inhibitor with improved selectivity and inhibitory activity.
Innovation Solution
A pyridinylpyrazole derivative or its pharmaceutically acceptable salt is designed based on hybridized QSAR models, exhibiting superior inhibitory activity against PLK1 and selective inhibition of other protein kinases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PLK1 inhibitors are developed to inhibit cell proliferation, then anticancer efficacy is improved, but cytotoxicity increases causing clinical trial failures
Solution Approach 1:
The patent applies local quality by designing a pyridinylpyrazole derivative with specific substituent patterns (R1-R6 groups) that create localized interactions with the PLK1 active site. The molecular structure features specific functional groups at defined positions that provide selective binding to PLK1 while avoiding off-target effects, thereby achieving high inhibitory activity against PLK1 with IC50 values in the nanomolar range without significant cytotoxicity
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as substituent types, positions, and stereochemistry of the pyridinylpyrazole core structure. Through QSAR analysis, specific parameter combinations were identified that optimize PLK1 binding affinity while maintaining selectivity, resulting in compounds with improved pharmacological profiles suitable for clinical development
2Object-affected harmful factors
If PLK1 inhibitor selectivity is improved to avoid off-target effects, then safety is enhanced, but inhibitory activity against PLK1 may be reduced
Solution Approach 1:
The patent applies segmentation by dividing the PLK1 binding site into distinct interaction regions that correspond to specific substituents on the pyridinylpyrazole core. The R1-R6 groups at different positions interact with specific residues in the PLK1 ATP-binding pocket, allowing independent optimization of selectivity and activity through modular structure design
Solution Approach 2:
The patent uses composite material principles by creating a hybrid molecular structure that combines the pyridinylpyrazole core with various aromatic and aliphatic substituents. This composite structure enables simultaneous optimization of PLK1 binding affinity and selectivity through careful selection of substituent combinations, achieving both high inhibitory activity and safety profile
Data Source
AI summary
The present disclosure relates to a pyridinylpyrazole derivative or a pharmaceutically acceptable salt thereof and a composition for preventing or treating a protein kinase-related disease, which contains the derivative or salt as an active ingredient. Since the pyridinylpyrazole derivative of the present disclosure exhibits cytotoxicity by inhibiting polo-like kinase 1 (PLK1), which induces cell proliferation, when administered to an individual, it can be used for prevention or treatment of a protein kinase-related disease, specifically for prevention or treatment of cancer.